Alvotech (NASDAQ: ALVO) announced a comprehensive restructuring of its global business development and commercial operations leadership team on October 22, 2025, as the biosimilar company positions itself for continued commercial expansion across international markets.
The most significant change involves Chief Commercial Officer Anil Okay stepping down from his role to serve as Chief Executive Officer of Adalvo. This transition represents a strategic shift as Alvotech seeks to strengthen its commercial capabilities under new leadership.
New Leadership Appointments
Trisha Durant has joined Alvotech as Senior Vice President, Global Business Development and Commercial Operation, ex-North America. Durant brings 18 years of pharmaceutical industry experience with a track record in strategy development, strategic alliances, revenue growth, and commercial team structuring. She joins from Biocon, where she most recently served as Head of Europe, leading commercial expansion efforts. Her previous experience includes 10 years at McKesson in various global roles and six years in Ernst & Young's Global Tax Advisory practice. Durant is based in the United Kingdom.
Harshika Sarbajna has been promoted to Senior Vice President Commercial, North America. Sarbajna joined Alvotech's commercial team in 2022 from Sandoz, where she led biosimilars and specialty products in the U.S. She previously served as Global Head of Marketing and Strategy for Sandoz within the anti-infectives and biosimilars businesses in Munich, Germany. Her 18-year career also includes strategy and strategic partnerships roles at Dr. Reddy's and management consulting at Parthenon for the U.S., Middle East, and Asia. Sarbajna is based in the United States.
Agne Pasko has been appointed Vice President Head of Business Development. Pasko joined Alvotech in 2019 and has held several senior roles in Commercial Operations, Supply Chain, and Business Development, driving revenue growth, new partnerships, and portfolio expansion. Prior to Alvotech, she managed development and marketing for 3P Pharmaceuticals, Northway Biotech, and Stem Cell RC. Pasko is based in Spain.
Strategic Context
"I want to thank Anil for his dedication and success in leading the expansion of Alvotech's commercial partnerships and operations. It is good to know that Adalvo, a company I founded and has been dear to my heart, is now in very capable hands," said Róbert Wessman, chairman and CEO of Alvotech. "I'm confident that with Trisha joining the team to manage commercial operations outside of North America, Harshika in charge of North American partnerships and Agne leading business development globally, we have a stellar leadership team for continuing commercial success of Alvotech."
Company Portfolio and Partnerships
Alvotech currently has two biosimilars approved and marketed in multiple global markets: biosimilars to Humira® (adalimumab) and Stelara® (ustekinumab). The company's development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer.
The company has established an extensive network of strategic commercial partnerships spanning global markets including the United States, Europe, Japan, China, other Asian countries, and large parts of South America, Africa, and the Middle East. Key commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd, Advanz Pharma, Dr. Reddy's, Biogaran, Cipla, JAMP Pharma Corporation, Yangtze River Pharmaceutical Group, DKSH, YAS Holding LLC, Abdi Ibrahim, Kamada Ltd., and Lotus Pharmaceuticals Co., Ltd., among others.
